More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world. But with increasing regulation, growing pricing pressures and competition for acquisitions, you face unprecedented challenges.
Ernst & Young has been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry. We’ve stayed committed to your business with our leading reports and our knowledgeable professionals. So it’s not surprising that we serve more biotech companies than any other professional services firm.
The Ernst & Young Global Biotechnology Center reflects our continuing commitment to biotechnology. It develops our thought leadership and brings you clear insights to address your assurance, tax, transaction and advisory needs. And it networks and educates our biotech professionals from around the world, so they are informed about the emerging issues impacting your business.
The bottom line? You receive a consistent, high-quality, seamless service — wherever you operate — and the help you need to meet your goals.
¿Cómo administrar su compañía durante la recesión y colocarla en buena posición para el crecimiento? Después de entrevistar a miles de ejecutivos de ciencias biológicas, identificamos algunos temas predominantes. Desde gestionar los riesgos hasta mejorar la asignación de capital, revelamos las lecciones que podrían; marcar la diferencia entre sobrevivir y prosperar en el nuevo entorno económico.
Olvidó su Nombre de Usuario o Contraseña
Return to Login
/$FILE/14L00241.JPG)